Cantor Fitzgerald set a $36.00 target price on Abeona Therapeutics (NASDAQ:ABEO) in a report released on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Abeona Therapeutics’ FY2018 earnings at ($0.97) EPS and FY2019 earnings at ($1.13) EPS.

Several other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Wednesday, August 15th. HC Wainwright set a $30.00 price objective on shares of Abeona Therapeutics and gave the company a buy rating in a report on Monday, August 13th. Maxim Group reiterated a buy rating and issued a $35.00 price objective on shares of Abeona Therapeutics in a report on Friday, August 10th. BidaskClub upgraded shares of Abeona Therapeutics from a sell rating to a hold rating in a report on Thursday, August 2nd. Finally, ValuEngine upgraded shares of Abeona Therapeutics from a buy rating to a strong-buy rating in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $28.30.

NASDAQ:ABEO opened at $13.25 on Friday. Abeona Therapeutics has a one year low of $7.45 and a one year high of $22.75. The firm has a market capitalization of $645.72 million, a price-to-earnings ratio of -20.08 and a beta of 1.37.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. The company had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.81 million. equities research analysts predict that Abeona Therapeutics will post -0.71 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Abeona Therapeutics by 0.3% in the first quarter. BlackRock Inc. now owns 1,873,472 shares of the biopharmaceutical company’s stock valued at $26,884,000 after acquiring an additional 5,094 shares in the last quarter. UBS Group AG grew its stake in shares of Abeona Therapeutics by 36.5% in the first quarter. UBS Group AG now owns 152,081 shares of the biopharmaceutical company’s stock valued at $2,182,000 after acquiring an additional 40,680 shares in the last quarter. Nexthera Capital LP acquired a new position in shares of Abeona Therapeutics in the first quarter valued at about $5,302,000. Knott David M acquired a new position in shares of Abeona Therapeutics in the first quarter valued at about $101,000. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Abeona Therapeutics by 11.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 62,852 shares of the biopharmaceutical company’s stock valued at $902,000 after acquiring an additional 6,500 shares in the last quarter. Institutional investors and hedge funds own 69.29% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Article: What does RSI mean?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.